B. Rafael Elejalde
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
B. Rafael Elejalde has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
John M. Opitz
11 shared publicationsMaria Mercedes de Elejalde
Genetics Section Mount Sinai Medical Center, Milwaukee, Wisconsin
7 shared publicationsMaria Mercedes De Elejalde
Medical Genetics Institute, 4555 West Schroeder Road, Suite 180, Brown Deer, WI53223, U.S.A.
6 shared publicationsJames F. Reynolds
5 shared publicationsRobert Roger Lebel
4 shared publicationsM M De Elejalde
Genetics Section, Department of Obstetrics and Gynecology, University of Wisconsin Medical School‐Milwaukee Clinical Campus, Mount Sinai Medical Center, Milwaukee
3 shared publications
Latest Publications
- 23 April 2008
- Published by Wiley in Clinical Genetics
- Vol. 16 (1) , 1-18
Hallervorden-Spatz disease
A family in which members (3 males, 2 female twins) were affected by the Hallervorden-Spatz disease was studied. The characteristics of the condition were analyzed and compared with other cases. Intrafamilial and interfamilial variations were analyzed, and it was established that the latter contributed most to the overall variation of the condition. This is probably an autosomal recessive condition (P > 0.23 .+-. 0.08), and it may have originated in Europe and may be caused by an inborn error of metabolism related to neuromelanin and the dopaminergic system. The condition affects the muscular tone and voluntary movements progressively, making voluntary coordinated movements, and chewing and swallowing almost impossible. In the last part of the disease progression, mental deterioration, emaciation, severe feeding difficulties and visual impairment are common clinical manifestations. The ages of both onset and death are distributed in a unimodal curve. The mean survival time after diagnosis is 11.18 .+-. 7.8 yr.
- 23 April 2008
- Published by Wiley in Clinical Genetics
- Vol. 16 (1) , 1-18
Hallervorden-Spatz disease
A family in which members (3 males, 2 female twins) were affected by the Hallervorden-Spatz disease was studied. The characteristics of the condition were analyzed and compared with other cases. Intrafamilial and interfamilial variations were analyzed, and it was established that the latter contributed most to the overall variation of the condition. This is probably an autosomal recessive condition (P > 0.23 .+-. 0.08), and it may have originated in Europe and may be caused by an inborn error of metabolism related to neuromelanin and the dopaminergic system. The condition affects the muscular tone and voluntary movements progressively, making voluntary coordinated movements, and chewing and swallowing almost impossible. In the last part of the disease progression, mental deterioration, emaciation, severe feeding difficulties and visual impairment are common clinical manifestations. The ages of both onset and death are distributed in a unimodal curve. The mean survival time after diagnosis is 11.18 .+-. 7.8 yr.
- 1 January 2002
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 23 (1) , 13-18
Single photon emission computerized tomography (SPECT) in detecting neurodegeneration in Huntingtonʼs disease
Single photon emission computerized tomography (SPECT) studies were performed on 34 manifest Huntington's disease (HD) patients at various stages of clinical pathology ranging from early chorea to late dystonia with or without signs of dementia and 12 pre-symptomatic patients with abnormal terminal CAG expansions. Thirty HD patients with obvious clinical signs and seven pre-symptomatic patients without signs or symptoms of HD displayed selective caudate hypoperfusion by direct visual inspection. Such qualitative, selective striatal hypoperfusion patterns can be indicative of early and persistent metabolic changes in striatal neuropathology. SPECT studies can be useful in documenting early pre-clinical changes in patients with abnormal terminal CAG expansions and in confirming the presence of caudate pathology in patients with clinical signs of HD.
- 1 January 2002
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 23 (1) , 13-18
Single photon emission computerized tomography (SPECT) in detecting neurodegeneration in Huntingtonʼs disease
Single photon emission computerized tomography (SPECT) studies were performed on 34 manifest Huntington's disease (HD) patients at various stages of clinical pathology ranging from early chorea to late dystonia with or without signs of dementia and 12 pre-symptomatic patients with abnormal terminal CAG expansions. Thirty HD patients with obvious clinical signs and seven pre-symptomatic patients without signs or symptoms of HD displayed selective caudate hypoperfusion by direct visual inspection. Such qualitative, selective striatal hypoperfusion patterns can be indicative of early and persistent metabolic changes in striatal neuropathology. SPECT studies can be useful in documenting early pre-clinical changes in patients with abnormal terminal CAG expansions and in confirming the presence of caudate pathology in patients with clinical signs of HD.
- 1 May 2001
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 68 (5) , 1102-1109
Up-Regulation of WNT-4 Signaling and Dosage-Sensitive Sex Reversal in Humans
- 1 May 2001
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 68 (5) , 1102-1109
Up-Regulation of WNT-4 Signaling and Dosage-Sensitive Sex Reversal in Humans
- 1 January 2000
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 116 (2) , 97-104
A Multicenter Investigation with D-FISH BCR/ABL1 Probes
- 1 January 2000
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 116 (2) , 97-104
A Multicenter Investigation with D-FISH BCR/ABL1 Probes
- 1 January 1995
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 172 (1) , 398
Prenatal diagnosis, histocompatibility testing and neonatal stem cell transplant in chediak-higashi disease
- 1 January 1995
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 172 (1) , 398
Prenatal diagnosis, histocompatibility testing and neonatal stem cell transplant in chediak-higashi disease
- 1 October 1994
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 31 (4) , 680-682
Linear facial skin defects associated with microphthalmia and other malformations, with chromosome deletion Xp22.1
- 1 October 1994
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 31 (4) , 680-682
Linear facial skin defects associated with microphthalmia and other malformations, with chromosome deletion Xp22.1
- 1 June 1994
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 112 (6) , 851-852
Gazali-Temple Syndrome
Research from JAMA Ophthalmology — Gazali-Temple Syndrome
- 1 June 1994
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 112 (6) , 851-852
Gazali-Temple Syndrome
Research from JAMA Ophthalmology — Gazali-Temple Syndrome
- 1 December 1993
- Published by Wiley in Prenatal Diagnosis
- Vol. 13 (12) , 1165-1166
45,X/46,XX/47,XXX phenotype
- 1 December 1993
- Published by Wiley in Prenatal Diagnosis
- Vol. 13 (12) , 1165-1166
45,X/46,XX/47,XXX phenotype
- 1 February 1990
- Published by Wiley in American Journal of Medical Genetics
- Vol. 35 (2) , 188-196
Prospective study of amniocentesis performed between weeks 9 and 16 of gestation: Its feasibility, risks, complications and use in early genetic prenatal diagnosis
This paper demonstrates that the outcome of amniocenteses performed between the 9th and the 14th weeks is similar to that of amniocenteses performed between the 15th and 20th weeks. We have performed and prospectively followed 615 amniocenteses between the 9th and 16th weeks of gestation. The outcome, risks, and complications are similar to those of amniocenteses at the usual time (after 15 weeks) and to the other groups of early amniocentesis (before 15 weeks). Early amniocentesis differs from amniocentesis at the usual time in that it carries higher rates of fetal losses and of amniotic fluid leakage, more confined cytogenetic abnormalities, and an increased number of patients who have the procedure postponed. Two cultures (0.32%) failed to produce results, 595 (96.7%) samples were obtained at the first tapping, 20 (3.3%) at the second attempt. α‐Fetoprotein levels reach their maximum at 13 weeks. Amniocenteses between 15 and 16 weeks (293, or 47%) constitute the control group, those between 9 and 14 weeks (322) the experimental group. Early amniocentesis appears to be a safe early genetic prenatal diagnosis technique, an alternative to chorionic villi sampling.
- 1 February 1990
- Published by Wiley in American Journal of Medical Genetics
- Vol. 35 (2) , 188-196
Prospective study of amniocentesis performed between weeks 9 and 16 of gestation: Its feasibility, risks, complications and use in early genetic prenatal diagnosis
This paper demonstrates that the outcome of amniocenteses performed between the 9th and the 14th weeks is similar to that of amniocenteses performed between the 15th and 20th weeks. We have performed and prospectively followed 615 amniocenteses between the 9th and 16th weeks of gestation. The outcome, risks, and complications are similar to those of amniocenteses at the usual time (after 15 weeks) and to the other groups of early amniocentesis (before 15 weeks). Early amniocentesis differs from amniocentesis at the usual time in that it carries higher rates of fetal losses and of amniotic fluid leakage, more confined cytogenetic abnormalities, and an increased number of patients who have the procedure postponed. Two cultures (0.32%) failed to produce results, 595 (96.7%) samples were obtained at the first tapping, 20 (3.3%) at the second attempt. α‐Fetoprotein levels reach their maximum at 13 weeks. Amniocenteses between 15 and 16 weeks (293, or 47%) constitute the control group, those between 9 and 14 weeks (322) the experimental group. Early amniocentesis appears to be a safe early genetic prenatal diagnosis technique, an alternative to chorionic villi sampling.
- 1 August 1986
- Published by Wiley in American Journal of Medical Genetics
- Vol. 24 (4) , 575-598
The prenatal growth of the human body determined by the measurement of bones and organs by ultrasonography
This paper presents the ultrasonographic analysis of the growth of two groups of human fetuses, one longitudinal and the other cross‐sectional. Measurements of all the long bones were taken, as well as measurements of the folowing diameters: Biparietal, occipitofrontal, thoracic and abdominal anterior/posterior and transverse, spinal canal width, arm, forearm, thigh and leg transverse. The bladder and the stomach were also measured. The pregnancies analyzed covered the period between the 8th and 38th week of gestation. Centiles (3rd‐97th) were calculated for each structure and week. All pregnancies known or suspected to be abnormal were removed from the study. The values obtained were tested in 102 pregnancies (test group); the expected values (from the graphs) did not deviate from the values obtained from this group of fetuses, demonstrating the reliability of the values presented in these graphs. All structures measured showed linear growth. There was no significant difference between the longitudinal and cross‐sectional groups.
- 1 August 1986
- Published by Wiley in American Journal of Medical Genetics
- Vol. 24 (4) , 575-598
The prenatal growth of the human body determined by the measurement of bones and organs by ultrasonography
This paper presents the ultrasonographic analysis of the growth of two groups of human fetuses, one longitudinal and the other cross‐sectional. Measurements of all the long bones were taken, as well as measurements of the folowing diameters: Biparietal, occipitofrontal, thoracic and abdominal anterior/posterior and transverse, spinal canal width, arm, forearm, thigh and leg transverse. The bladder and the stomach were also measured. The pregnancies analyzed covered the period between the 8th and 38th week of gestation. Centiles (3rd‐97th) were calculated for each structure and week. All pregnancies known or suspected to be abnormal were removed from the study. The values obtained were tested in 102 pregnancies (test group); the expected values (from the graphs) did not deviate from the values obtained from this group of fetuses, demonstrating the reliability of the values presented in these graphs. All structures measured showed linear growth. There was no significant difference between the longitudinal and cross‐sectional groups.